peptide mapping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
== Sources == Benjamin, Denis R. (1995). Mushrooms: poisons and panaceas — a handbook for naturalists, mycologists and physicians. New York: WH Freeman and Company. ISBN 978-0-7167-2600-5. Jordan Peter; Wheeler Steven. (2001). The Ultimate Mushroom Book. London: Hermes House. ISBN 978-1-85967-092-7.
Some analyses of traditional preparations of San Pedro cactus have found doses ranging from 34 mg to 159 mg of total alkaloids, a relatively low and barely psychoactive amount. It appears that patients who receive traditional treatments with San Pedro ingest sub-psychoactive doses and do not experience psychedelic effects. The onset of the effects of mescaline given orally is 0.5 to 0.9 hours on average with a range of 0.1 to 2.7 hours. Its effects peak after 1.9 to 4.0 hours with a range of 0.5 to 8.0 hours. The duration of mescaline appears to be dose-dependent, varying from 6.4 hours on average (range 3.0–10 hours) at a dose of 100 mg, 9.7 to 11 hours on average (range 5.6–22 hours) at moderate doses of 300 to 500 mg, and 14 hours on average (range 7.2–22 hours) at a dose of 800 mg. Cases of mescaline having unusually prolonged or delayed effects have also been described. Given intravenously, mescaline has been reported to have an onset of several minutes or within 10 minutes, a time to peak of 1 to 2 hours, and a duration of approximately 4 to 9 hours in different studies. Mescaline induces a psychedelic state comparable to those produced by LSD and psilocybin, but with unique characteristics. Subjective effects may include altered thinking processes, an altered sense of time and self-awareness, and closed- and open-eye visual phenomena. In PiHKAL, Shulgin described the effects of mescaline based on a collection of experience reports.
=== Intrinsically disordered proteins === Intrinsically disordered proteins lack a fixed or ordered three-dimensional structure. IDPs cover a spectrum of states from fully unstructured to partially structured and include random coils, (pre-)molten globules, and large multi-domain proteins connected by flexible linkers. They constitute one of the main types of protein (alongside globular, fibrous and membrane proteins).
Tapering off of methadone maintenance DE patent 711069, Dr Max Bockmuehl & Dr Gustav Ehrhart, "Verfahren zur Darstellung von basischen Estern", published 25 September 1941, issued 25 September 1941, assigned to IG Farbenindustrie AG Archived 13 February 2023 at the Wayback Machine
==== Methylnaltrexone bromide ==== Methylnaltrexone bromide is the bromide salt form of methylnaltrexone, a quaternary methyl derivative of noroxymorphone. The methyl group and the quaternary salt formation increase the polarity and reduce the lipid solubility thereby restricts the blood–brain-barrier penetration. Methylnaltrexone has eight times higher affinity for MOR than for κ-opioid receptor (KOR) and δ-opioid receptor (DOR). Naltrexone forms interaction with Asp147 and Tyr148 along with a hydrogen bond with Lys233.
Sources: en.wikipedia.org
A synovial joint, also known as diarthrosis, joins bones or cartilage with a fibrous joint capsule that is continuous with the periosteum of the joined bones, constitutes the outer boundary of a synovial cavity, and surrounds the bones' articulating surfaces. This joint unites long bones and permits free bone movement and greater mobility. The synovial cavity/joint is filled with synovial fluid. The joint capsule is made up of an outer layer of fibrous membrane, which keeps the bones together structurally, and an inner layer, the synovial membrane, which seals in the synovial fluid. They are the most common and most movable type of joint in the body. As with most other joints, synovial joints achieve movement at the point of contact of the articulating bones. Joints that are not synovial include fibrous joints such as the joints in the cranium, and cartilaginous joints such as intervertebral discs. Synovial joints originated 400 million years ago in the first jawed vertebrates.
== External links == Suttas Mahā Nidāna Sutta at dhammatalks.org SN 12.1: Paticca-samuppada-vibhanga Sutta SN 12.23: Upanisa Sutta, translation by Bhikkhu Thanissaro SN 12.23: Upanisa Sutta, translation and exposition by Bhikkhu Bodhi Commentaries Pratītyasamutpāda by Alawwe Anōmadassi Thero Dependent Origination: the Buddhist Law of Conditionality, by Prayudh Payutto Paticcasamuppada: Practical Dependent Origination, by Buddhadasa The Doctrine of Paticcasamuppada, U Than Daing A Discourse on Paticcasamuppada, Mahasi Sayadaw The Shape of Suffering: A study of Dependent Co-arising, Bhikkhu Thanissaro (2008) Educational Resources
=== Pharmacokinetics === After being ingested, clonidine is absorbed into the blood stream rapidly with an overall bioavailability around 70–80%. Peak concentrations in human plasma occur within 60–90 minutes for the "immediate release" (IR) version of the drug, which is shorter than the "extended release" (ER/XR) version. Clonidine is fairly lipid soluble with the logarithm of its partition coefficient (log P) equal to 1.6; to compare, the optimal log P to allow a drug that is active in the human central nervous system to penetrate the blood brain barrier is 2.0. Less than half of the absorbed portion of an orally administered dose will be metabolized by the liver into inactive metabolites, with roughly the other half being excreted unchanged by the kidneys. About one-fifth of an oral dose will not be absorbed, and is thus excreted in the feces. Work with liver microsomes shows in the liver clonidine is primarily metabolized by CYP2D6 (66%), CYP1A2 (10–20%), and CYP3A (0–20%) with negligible contributions from the less abundant enzymes CYP3A5, CYP1A1, and CYP3A4. 4-hydroxyclonidine, the main metabolite of clonidine, is also an α2A agonist but is non lipophilic and is not believed to contribute to the effects of clonidine since it does not cross the blood–brain barrier. Measurements of the half-life of clonidine vary widely, between 6 and 23 hours, with the half-life being greatly affected by and prolonged in the setting of poor kidney function. Variations in half-life may be partially attributable to CYP2D6 genetics.
Plague of Justinian, from 541 to 542, killed between 50% and 60% of Europe's population. The Black Death of 1347 to 1352 killed 25 million in Europe over five years. The plague reduced the old world population from an estimated 450 million to between 350 and 375 million in the 14th century. The introduction of smallpox, measles, and typhus to the areas of Central and South America by European explorers during the 15th and 16th centuries caused pandemics among the native inhabitants. Between 1518 and 1568 disease pandemics are said to have caused the population of Mexico to fall from 20 million to 3 million. The first European influenza epidemic occurred between 1556 and 1560, with an estimated mortality rate of 20%. Smallpox killed an estimated 60 million Europeans during the 18th century (approximately 400,000 per year). Up to 30% of those infected, including 80% of the children under 5 years of age, died from the disease, and one-third of the survivors went blind. In the 19th century, tuberculosis killed an estimated one-quarter of the adult population of Europe; by 1918 one in six deaths in France were still caused by TB. The Influenza Pandemic of 1918 (or the Spanish flu) killed 25–50 million people (about 2% of world population of 1.7 billion). Today Influenza kills about 250,000 to 500,000 worldwide each year. In 2021, COVID-19 emerged as a major global health crisis, directly causing 8.7 million deaths, making it one of the leading causes of mortality worldwide.
Sources: en.wikipedia.org
==== Oral cleaning agent ==== The use of dilute hydrogen peroxide as an oral cleansing agent has been reviewed academically to determine its usefulness in treating gingivitis and plaque. Although there is a positive effect when compared with a placebo, it was concluded that chlorhexidine is a much more effective treatment.
=== History === Nitro cold brew was first offered at third wave coffee shops in the early 2010s, but the exact origin is disputed. It may have originated in 2013 at the craft coffee houses Cuvee Coffee in Austin, Texas, and Stumptown in Portland, Oregon. The draft coffee at the Queens Kickshaw in New York in 2011 may be a predecessor. Cuvee Coffee first offered nitro cold brew, on tap, at the Slow Food Quiz Bowl in Austin, Texas, on August 14, 2012. The Ball Corporation issued a press release citing Cuvee as the first company to can cold brew in their widget cans, and BevNet awarded Cuvee the Best Packaging Innovation, calling them "the first cold brew brand to market a nitrogenated offering." Stumptown and Cuvee began offering canned beverages with a nitrogen-filled capsule to pressurize the can by 2015. Starbucks introduced the beverage at 500 stores in the summer of 2016, preceded in the Los Angeles market by The Coffee Bean & Tea Leaf. By 2020, Starbucks offered the beverage at more than half of its locations across the United States, making it a staple menu item. Nitro cold brew is available from wholesalers in some markets in kegs. RISE Brewing Co. says it can fill up to 1,500 kegs a day of nitro cold brew coffee.
== Early life and education == Freeman was born on June 1, 1937, in Memphis, Tennessee. He is the son of Mamie Edna (née Revere; 1912–2000), a teacher, and Morgan Porterfield Freeman (July 6, 1915 – April 27, 1961), a barber, who died of cirrhosis in 1961. He has three older siblings. Some of Morgan's great-great-grandparents were slaves who migrated from North Carolina to Mississippi. He later discovered that his white maternal great-great-grandfather had lived with and was buried beside Freeman's black great-great-grandmother in the segregated South, as the two could not legally marry at the time. A DNA test suggested that among all of his African ancestors, a little over one-quarter came from the area that stretches from present-day Senegal to Liberia and three-quarters came from the Congo-Angola region. As an infant, Freeman was sent to his paternal grandmother in Charleston, Mississippi. He moved frequently during his childhood, living in Greenwood, Mississippi, Gary, Indiana, and finally Chicago. He made his acting debut aged nine, playing the lead role in a school play. He then attended Broad Street High School, a building which serves today as Threadgill Elementary School in Greenwood. At the age of 12, he won a statewide drama competition, and while settling into school, discovered music and theater. When Freeman was 16 years old, he contracted pneumonia. Freeman graduated from high school in 1955, but turned down a partial drama scholarship from Jackson State University, opting instead to enlist in the United States Air Force.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.